BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 21, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Viva in vivo! At EHA, in vivo CAR T data continues to impressBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

3D illustration of acute lymphoblastic leukemia in blood.
Cancer

Oncolytic measles virus shows activity in pediatric leukemia

Jan. 23, 2026
No Comments
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common pediatric cancer. Although pediatric ALL is cured in over 90% of cases, children with high-risk BCP-ALL present increased chance of treatment failure and relapse.
Read More
Illustration of kidneys floating over gloved hand
Nephrology

PGC-1α gene delivery protects against kidney reperfusion injury

Jan. 23, 2026
No Comments
Renal ischemia-reperfusion injury (IRI) is a type of acute kidney injury commonly affecting hospitalized patients and associated with poor outcomes, including increased risk of death in severe cases. IRI is caused by a transient reduction in renal blood flow followed by blood reperfusion.
Read More
Endocrine/metabolic

Alveus Therapeutics’ ALV-100 gains IND clearance for obesity

Jan. 23, 2026
No Comments
Alveus Therapeutics Inc. has obtained IND clearance from the FDA for ALV-100, for chronic weight management, enabling initiation of a phase Ib study. Dosing has now commenced in the study.
Read More
Illustration of bacteria in the bloodstream
Infection

Age impacts disease tolerance to sepsis, study shows

Jan. 23, 2026
By Xavier Bofill Bruna
No Comments
The immune system is a critical factor of host survival, allowing resistance to infections and maintaining tissue integrity. The activation of immune responses requires precise regulation to assure a balance between the benefits and costs of these responses. Moreover, the theory of antagonistic pleiotropy proposes that traits beneficial to early-life fitness may sustain costs that manifest later in life, after the period of strongest natural selection, where aging introduces further complexities for cooperative defenses. As a result of this, hosts of different ages may manifest distinct disease courses despite infection with the same pathogen.
Read More
Neurology/psychiatric

Chengdu Kanghong Pharmaceutical patents LRRK2 inhibitors

Jan. 23, 2026
Chengdu Kanghong Pharmaceutical Co. Ltd. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, type 1 diabetes, glaucoma, inflammatory bowel disease, multiple sclerosis, neurodegeneration, psoriasis and rheumatoid arthritis, among others.
Read More
Respiratory

Beijing Tide Pharmaceutical divulges new cathepsin C inhibitors

Jan. 23, 2026
Beijing Tide Pharmaceutical Co. Ltd. has patented new cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of bronchiectasis.
Read More
Cancer

Acerand Therapeutics discovers new CYP11A1 inhibitors

Jan. 23, 2026
Acerand Therapeutics (Hong Kong) Ltd. has divulged new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Bio-Thera Solutions identifies new HER2-targeted antibody-drug conjugates

Jan. 23, 2026
Bio-Thera Solutions Ltd. has synthesized new antibody-drug conjugates comprising trastuzumab targeting HER2 (erbB2) covalently linked to exatecan through a linker reported to be useful for the treatment of cancer, inflammation, autoimmune disorders and infections.
Read More
Infection

Centre Hospitalier Regional Universitaire de Lille divulges new 3CLpro inhibitors

Jan. 23, 2026
Centre Hospitalier Regional Universitaire de Lille has patented new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Read More
Cancer

Sunshine Lake Pharma divulges new PKMYT1 inhibitors

Jan. 22, 2026
Sunshine Lake Pharma Co. Ltd. has patented new PKMYT1 inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.
Read More
Previous 1 2 … 133 134 135 136 137 138 139 140 141 … 18102 18103 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • Wireframe of feet and scale

    GLP-1s need technologies for long-term use

    BioWorld
    For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
  • UTRN gene involved in arthrogryposis, study finds

    BioWorld Science
    Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
  • Blue-gray dollar sign

    HMNC raises $50M series B to prep depression drugs for phase III

    BioWorld
    HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
  • Illustration of glucose in the blood stream

    CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

    BioWorld Science
    Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing